Sensei Biotherapeutics (NASDAQ:FTH) Stock Rating Reaffirmed as “Buy” by HC Wainwright

Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They currently have a $60.00 target price on the stock. HC Wainwright‘s price target would indicate a potential upside of 498.21% from the company’s current price. HC Wainwright also issued estimates for Sensei Biotherapeutics’ Q4 2026 earnings at ($0.82) EPS, FY2026 earnings at ($15.52) EPS, Q1 2027 earnings at ($0.84) EPS, Q2 2027 earnings at ($0.87) EPS, Q3 2027 earnings at ($0.90) EPS, Q4 2027 earnings at ($0.97) EPS, FY2027 earnings at ($3.60) EPS, FY2028 earnings at ($3.23) EPS, FY2029 earnings at ($3.10) EPS and FY2030 earnings at ($3.09) EPS.

FTH has been the topic of several other research reports. Oppenheimer began coverage on shares of Sensei Biotherapeutics in a report on Tuesday, July 28th. They set an “outperform” rating and a $60.00 target price on the stock. Guggenheim dropped their price objective on Sensei Biotherapeutics from $70.00 to $69.00 and set a “buy” rating on the stock in a report on Wednesday, November 4th. Lifesci Capital raised Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, October 15th. Citizens Jmp began coverage on Sensei Biotherapeutics in a research note on Monday, July 20th. They set an “outperform” rating and a $51.00 target price for the company. Finally, TD Cowen initiated coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, September 9th. They issued a “buy” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Sensei Biotherapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $56.58.

Read Our Latest Report on FTH

Sensei Biotherapeutics Price Performance

FTH opened at $10.03 on Monday. Sensei Biotherapeutics has a 1 year low of $7.45 and a 1 year high of $42.14. The business has a 50 day moving average of $25.07. The firm has a market capitalization of $259.18 million, a PE ratio of -0.07 and a beta of -0.14.

Sensei Biotherapeutics (NASDAQ:FTH – Get Free Report) last announced its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.13). On average, research analysts expect that Sensei Biotherapeutics will post -14.01 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. State of Wyoming bought a new stake in shares of Sensei Biotherapeutics during the 3rd quarter valued at about $25,000. China Universal Asset Management Co. Ltd. raised its stake in Sensei Biotherapeutics by 48.9% during the third quarter. China Universal Asset Management Co. Ltd. now owns 5,360 shares of the company’s stock worth $150,000 after acquiring an additional 1,760 shares during the period. Citadel Advisors LLC acquired a new stake in Sensei Biotherapeutics during the second quarter worth about $307,000. Jump Financial LLC acquired a new stake in shares of Sensei Biotherapeutics during the 3rd quarter worth approximately $694,000. Finally, Renaissance Technologies LLC lifted its stake in Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after buying an additional 20,525 shares during the last quarter. 10.50% of the stock is owned by institutional investors and hedge funds.

Sensei Biotherapeutics Company Profile

(Get Free Report)

Sensei Biotherapeutics is a biotechnology company focused on developing immunotherapies for cancer. Its research centers on treatments intended to address immune suppression in the tumor microenvironment and help the body’s immune system recognize and attack cancer cells. The company’s publicly disclosed research programs have included SNS-101, an antibody designed to target VISTA, an immune checkpoint protein, and SNS-301, an investigational cancer immunotherapy. These programs were in development rather than marketed products.

See Also

Analyst Recommendations for Sensei Biotherapeutics (NASDAQ:FTH)

Receive News & Ratings for Sensei Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensei Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.